Advertisement

Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Dr. Liu on the Development of Frontline Atezolizumab Combination Therapies in SCLC

November 29th 2022

Stephen V. Liu, MD, discusses efforts to develop atezolizumab-based combination therapies for patients with small cell lung cancer.

ARRY-614 Plus Immune Checkpoint Inhibition Can Induce Durable Responses in Advanced Solid Tumors

November 28th 2022

The combination of the p38 MAPK inhibitor ARRY-614 plus nivolumab with or without ipilimumab was well tolerated and elicited disease control in high-risk, PD-(L)1–refractory patients with advanced solid tumors.

FDA Issues Complete Response Letter to Poziotinib for Metastatic NSCLC Harboring HER2 Exon 20 Mutations

November 28th 2022

The FDA has issued a complete response letter to the new drug application seeking the approval of poziotinib for the treatment of patients with previously treated locally advanced or metastatic non–small cell lung cancer with HER2 exon 20 insertion mutations.

Perspectives From the Frontline: What Is Happening on the Ground With NGS Testing in NSCLC?

November 28th 2022

Benjamin P. Levy, MD; Bhuvana Ramkumar, MD; and Neil Morganstein, MD, discuss the challenges with tissue testing facing care teams, as well as multilevel hurdles in procurement, analysis of results, and insurance.

Halmos Highlights Immunotherapy Treatment Decisions, Emerging ADCs in NSCLC

November 25th 2022

Balazs Halmos, MD, discusses the role of immunotherapy in the frontline setting of NSCLC and the emerging pipeline of antibody-drug conjugates that could affect the treatment paradigm in lung cancer.

Innovative Trajectory Built From Tradition

November 24th 2022

Roy S. Herbst, MD, PhD, helped usher in the age of targeted therapy and immunotherapy in lung cancer, turning an almost hopeless disease into a condition that can be treated and even cured.

The Exciting Future of NSCLC Treatment

November 23rd 2022

Closing their discussion, the panel shares where they think the NSCLC treatment landscape will be in the future, and what to look forward to.

HARMONIC Evaluates Novel Combination in Growing Population of Never Smokers With Advanced Lung Cancer

November 22nd 2022

In combination with standard-of-care carboplatin and pemetrexed, the investigational agent LP-300 will be evaluated in never smokers with non–small cell lung cancer in the phase 2 HARMONIC study.

Quality Improvement Project Shows Reduced Time From Diagnosis to NGS in Patients With NSCLC

November 21st 2022

The median time between pathologic diagnosis to next-generation sequencing was reduced in a quality improvement project for patients with newly diagnosed metastatic non–small cell lung cancer.

FDA Grants Orphan Drug Designation to Vebreltinib for NSCLC With MET Aberrations

November 17th 2022

The FDA has granted an orphan drug designation to vebreltinib for the treatment of patients with non–small cell lung cancer harboring MET genomic tumor aberrations.

NICE Recommends Mobocertinib for Rare, Aggressive Lung Cancer

November 16th 2022

The United Kingdom’s National Institute for Health and Care Excellence has issued final guidance recommending the use of mobocertinib for patients with advanced non-small-cell lung cancer harboring EGFR exon 20 insertion mutations who have already received platinum-based chemotherapy.

Ivonescimab Receives Breakthrough Therapy Designation for IO-Resistant NSCLC in China

November 16th 2022

The Center for Drug Evaluation of the China National Medical Products Administration has granted a breakthrough therapy designation to ivonescimab plus docetaxel for patients with locally advanced or metastatic non–small cell lung cancer who failed to respond to a prior PD-(L)1 inhibitor plus platinum-based doublet chemotherapy.

A Role for Immunotherapy in Patients with Concomitant KRAS and KEAP1/STK11/p53 Mutations

November 16th 2022

The panel explains their approaches to treating patients with mutated NSCLC with immunotherapy.

The ARC-7 Trial of Anti-TGIT Immunotherapies in Advanced NSCLC

November 16th 2022

Dr Johnson reviews data from the ARC-7 trial investigating an anti-PD-L1 plus anti-TGIT combination treatment for advanced NSCLC.

Dr. Halmos on Trastuzumab Deruxtecan in NSCLC

November 14th 2022

Balazs Halmos, MD, discusses the importance of testing for HER2 mutations and exon 20 insertions, which are emerging new targets in non–small cell lung cancer, and how fam-trastuzumab deruxtecan-nxki meets needs for patients with HER2-mutant disease.

Dr. Kris on Immunotherapy in NSCLC Without Driver Mutations

November 14th 2022

Mark G. Kris, MD, discusses the role of immunotherapy in patients with non–small cell lung cancer without driver mutations.

Checkpoint Inhibitor Challenges Warrant Consideration for a Targeted Approach in NSCLC

November 14th 2022

In treating patients with locally advanced non–small cell lung cancer, one must consider multiple factors when deciding whether to treat them with immunotherapy or a targeted approach, even though the optimal treatment sequence has yet to be definitively established.

Osimertinib Remains the Preferred Frontline Choice for EGFR-Mutated NSCLC

November 14th 2022

Osimertinib remains the preferred first-line therapy for patients with EGFR-mutated non–small cell lung cancer. However, for those with classic EGFR mutations, the day is fast approaching when physicians will add chemotherapy to first-line treatment with the EGFR TKI based on ctDNA results.

Targeting the ‘New Kids on the Block’ in NSCLC: EGFR Exon 20 and MET Exon 14 Skipping Mutations

November 14th 2022

Investigators are harnessing comprehensive molecular profiling to detect new targets, optimize existing treatment regimens, and develop novel therapies for patients with EGFR and MET exon 20–insertion positive non–small cell lung cancer.

CYNK-101 Plus Avelumab Mediates ADCC Activity in Select PD-L1+ Solid Tumors

November 13th 2022

CYNK-101 demonstrated synergistic activity when used in combination with avelumab through antibody-dependent cellular cytotoxicity against PD-L1–positive non–small cell lung cancer, triple-negative breast cancer, and bladder cancer cell lines, according to preclinical data.

Advertisement
Advertisement